RU2018140988A - Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 - Google Patents
Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 Download PDFInfo
- Publication number
- RU2018140988A RU2018140988A RU2018140988A RU2018140988A RU2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A RU 2018140988 A RU2018140988 A RU 2018140988A
- Authority
- RU
- Russia
- Prior art keywords
- vector
- peptide
- vectors
- inflammation
- interleukin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 20
- 108090000174 Interleukin-10 Proteins 0.000 title claims 15
- 102000003814 Interleukin-10 Human genes 0.000 title claims 10
- 229940076144 interleukin-10 Drugs 0.000 title claims 9
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 239000013598 vector Substances 0.000 claims 13
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 3
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 235000004400 serine Nutrition 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 210000004507 artificial chromosome Anatomy 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 239000013601 cosmid vector Substances 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000000497 foam cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Claims (21)
1. Способ лечения воспаления у субъекта, включающий экспрессию с одного или нескольких бактериальных, вирусных, фаговых, космидных векторов или векторов на основе искусственной хромосомы пептида интерлейкина 10 (IL-10) и пептида рецептора интерлейкина 10 типа 1 (IL-10R1) в антигенпредставляющих клетках у субъекта.
2. Способ по п.1, где пептид IL-10, экспрессированный в антигенпредставляющих клетках, содержит мутацию в шарнирной области пептида IL-10.
3. Способ по п.2, где пептид IL-10 содержит мутацию, где фенилаланин в положении 129 последовательности IL-10 дикого типа заменен на серин, треонин, аланин или цистеин.
4. Способ по п.3, где фенилаланин в положении 129 последовательности дикого типа заменен на серин.
5. Способ по п.1, где IL-10 и IL-10R1 экспрессируются с одного вектора.
6. Способ по п.5, где вектор представляет собой вирусный вектор.
7. Способ по п.6, где вирусный вектор представляет собой аденоассоциированный вирусный вектор.
8. Способ по п.6, где вирусный вектор представляет собой лентивирусный вектор.
9. Способ по п.5, где кодирующие последовательности IL-10 и IL-10R1 транскрибируются в форме одной мРНК.
10. Способ по п.9, где вектор дополнительно содержит кодирующую последовательность для внутреннего участка связывания рибосомы между кодирующими последовательностями IL-10 и IL-10R1.
11. Способ по п.9, где вектор дополнительно содержит кодирующую последовательность для саморасщепляющегося пептида 2a между кодирующими последовательностями IL-10 и IL-10R1.
12. Способ по п.1, где воспаление вызвано нейропатической или хронической болью, и один или несколько векторов доставляют посредством интратекальной инъекции.
13. Способ по п.1, где воспаление вызвано MS, и один или несколько векторов доставляют посредством интратекальной инъекции.
14. Способ по п.1, где воспаление вызвано аутоиммунным заболеванием, и один или несколько векторов доставляют посредством интратекальной инъекции.
15. Способ по п.1, где воспаление локализовано в суставе, и один или несколько векторов доставляют посредством интраартикулярной инъекции.
16. Способ по п.1, где воспаление представляет собой нейровоспаление.
17. Способ по п.1, где антигенпредставляющие клетки выбраны из группы из монобластов, моноцитов, астроцитов, олигодендроцитов, микроглии, макрофагов, В-клеток, дендритных клеток, пенистых клеток, лимфобластов и В-лимфоцитов.
18. Способ по п.17, где антигенпредставляющие клетки отбирают у субъекта, подлежащего лечению, трансдуцируют одним или несколькими векторами in vitro и вводят обратно субъекту.
19. Способ по п.17, где антигенпредставляющие клетки стабильно трансформируют одним или несколькими векторами и поддерживают в культуре.
20. Одиночный вирусный или бактериальный экспрессирующий вектор, содержащий кодирующие области для интерлейкина 10 (IL-10) и рецептора интерлейкина 10 типа 1 (IL-10R1).
21. Одиночный экспрессирующий вектор по п.20, где вектор представляет собой вирусный вектор, содержащий один промотор, управляющий транскрипцией пептидов IL-10 и IL-10R1, и дополнительно содержит саморасщепляющийся пептид 2a, расположенный между кодирующей областью пептида IL-10 и кодирующей областью пептида IL-10R1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326082P | 2016-04-22 | 2016-04-22 | |
| US62/326,082 | 2016-04-22 | ||
| PCT/US2017/028755 WO2017184933A1 (en) | 2016-04-22 | 2017-04-21 | Methods and compositions to enhance the anti-inflammatory effects of interleukin 10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018140988A true RU2018140988A (ru) | 2020-05-22 |
| RU2018140988A3 RU2018140988A3 (ru) | 2020-05-25 |
| RU2731160C2 RU2731160C2 (ru) | 2020-08-31 |
Family
ID=60116475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018140988A RU2731160C2 (ru) | 2016-04-22 | 2017-04-21 | Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190112354A1 (ru) |
| EP (1) | EP3445849B1 (ru) |
| JP (2) | JP7163189B2 (ru) |
| KR (1) | KR102430455B1 (ru) |
| CN (1) | CN109477085B (ru) |
| AU (1) | AU2017252327B2 (ru) |
| CA (1) | CA3019846A1 (ru) |
| DK (1) | DK3445849T3 (ru) |
| IL (1) | IL262195B2 (ru) |
| RU (1) | RU2731160C2 (ru) |
| WO (1) | WO2017184933A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042463T2 (hu) | 2013-07-18 | 2019-07-29 | Univ Colorado Regents | Készítmény gyulladásos ízületi betegség kezelésére |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| AU2019275409B2 (en) | 2018-05-24 | 2024-08-15 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| WO2021093790A1 (en) * | 2019-11-11 | 2021-05-20 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| KR102466921B1 (ko) * | 2021-06-29 | 2022-11-14 | 주식회사 오에이티씨 | 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물 |
| WO2023114958A1 (en) * | 2021-12-16 | 2023-06-22 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716804A (en) * | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| EP1891103B1 (en) * | 2005-05-31 | 2009-12-23 | The Regents of the University of Colorado | Mutant il-10 |
| CN103038343A (zh) * | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用 |
| US9315825B2 (en) * | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| WO2013103966A1 (en) * | 2012-01-06 | 2013-07-11 | The Regents Of The University Of Colorado, A Body Corporate | Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| HUE042463T2 (hu) * | 2013-07-18 | 2019-07-29 | Univ Colorado Regents | Készítmény gyulladásos ízületi betegség kezelésére |
-
2017
- 2017-04-21 US US16/094,006 patent/US20190112354A1/en not_active Abandoned
- 2017-04-21 CN CN201780025135.5A patent/CN109477085B/zh active Active
- 2017-04-21 CA CA3019846A patent/CA3019846A1/en active Pending
- 2017-04-21 DK DK17786683.7T patent/DK3445849T3/da active
- 2017-04-21 RU RU2018140988A patent/RU2731160C2/ru active
- 2017-04-21 JP JP2018555141A patent/JP7163189B2/ja active Active
- 2017-04-21 EP EP17786683.7A patent/EP3445849B1/en active Active
- 2017-04-21 IL IL262195A patent/IL262195B2/en unknown
- 2017-04-21 WO PCT/US2017/028755 patent/WO2017184933A1/en active Application Filing
- 2017-04-21 AU AU2017252327A patent/AU2017252327B2/en active Active
- 2017-04-21 KR KR1020187033641A patent/KR102430455B1/ko active IP Right Grant
-
2022
- 2022-08-04 JP JP2022124716A patent/JP2022169585A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7163189B2 (ja) | 2022-10-31 |
| RU2731160C2 (ru) | 2020-08-31 |
| IL262195B1 (en) | 2023-05-01 |
| RU2018140988A3 (ru) | 2020-05-25 |
| EP3445849A4 (en) | 2019-09-25 |
| IL262195A (en) | 2018-11-29 |
| KR102430455B1 (ko) | 2022-08-05 |
| AU2017252327B2 (en) | 2023-05-25 |
| AU2017252327A1 (en) | 2018-11-15 |
| JP2022169585A (ja) | 2022-11-09 |
| DK3445849T3 (da) | 2024-08-05 |
| IL262195B2 (en) | 2023-09-01 |
| US20190112354A1 (en) | 2019-04-18 |
| EP3445849A1 (en) | 2019-02-27 |
| CN109477085B (zh) | 2023-08-01 |
| JP2019518003A (ja) | 2019-06-27 |
| EP3445849B1 (en) | 2024-06-05 |
| KR20190021211A (ko) | 2019-03-05 |
| WO2017184933A1 (en) | 2017-10-26 |
| CA3019846A1 (en) | 2017-10-26 |
| CN109477085A (zh) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018140988A (ru) | Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 | |
| JP2019518003A5 (ru) | ||
| JP6893945B2 (ja) | Ｔａｌｅｎに基づく遺伝子修正 | |
| Molnarfi et al. | Hepatocyte growth factor: A regulator of inflammation and autoimmunity | |
| Cheroutre et al. | CD4 CTL: living up to the challenge | |
| CN113454110A (zh) | Ny-eso-1 t细胞受体和其使用方法 | |
| JP5980508B2 (ja) | 自己免疫障害に対する処置方法 | |
| CA2963362A1 (en) | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation | |
| Kim et al. | Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa | |
| AU2016220324B2 (en) | A fully-human T cell receptor specific for the 369-377 epitope derived from the HER2/Neu (ERBB2) receptor protein | |
| Abraham et al. | IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion | |
| Schäffler et al. | The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21. 3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH) | |
| US20210380683A1 (en) | Modulation of irf-4 and uses thereof | |
| US20150110737A1 (en) | Methods of producing and using regulatory b-cells | |
| CN118240767A (zh) | 作为减少或预防转移、治疗自身免疫和炎性病症以及重新平衡免疫环境和失调的小生境的平台的基因修饰的hspc及间充质细胞 | |
| Mondanelli et al. | Islet antigen-pulsed dendritic cells expressing ectopic IL-35Ig protect nonobese diabetic mice from autoimmune diabetes | |
| WO2019071029A1 (en) | PREVENTION AND TREATMENT OF GVHD AND OTHER AUTOIMMUNE DISEASES | |
| Cheng et al. | Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment | |
| CA3137808A1 (en) | Cd5 specific t cell receptor cell or gene therapy | |
| Cap et al. | Lymphatic PD-L1 expression restricts tumor-specific CD8+ T cell responses | |
| ES2972793T3 (es) | Células diseñadas para inducir tolerancia | |
| Horn et al. | Gene therapy in the transplantation of allogeneic organs and stem cells | |
| JP2015136293A (ja) | 腎細胞癌の予防又は治療に好適なペプチド、核酸分子、及びベクター、並びにそれらの利用 | |
| Yang et al. | Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene | |
| Kostine | Briaire-de Brui n, IH, Cle en |